Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
May 1, 2026
Reporting period
Not applicable
Filed with the SEC
May 5, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000875320-26-000193
Filed / recorded
May 5, 2026, 9:44 PM UTC
Added to OQRO
Oct 2, 2026, 12:28 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
VERTEX PHARMACEUTICALS INC / MA
Issuer CIK
875320
Ticker
VRTX
Reporting person
Suketu Upadhyay
Relationship
Director
Security
Deferred Stock Units
Table
Derivative (Table II)
Transaction date
May 1, 2026
Transaction code
A
Shares / units
796
Acquired / disposed
Acquired (A)
Shares owned after
3,595.156
Ownership form
Direct
Amendment
No
Footnotes from the filing
Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.
Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.
73 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 22, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Changed a top executive or board member, and held a shareholder vote
“On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the "2026 Plan"), which replaces the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan, subject to shareholder approval.”